Australia has officially approved the use of milk fat globule membrane (MFGM) in infant formula, granting Arla Foods Ingredients exclusive rights to commercialise this component in the country.
The approval marks a milestone for Arla Foods Ingredients, as their product, Lacprodan MFGM-10, becomes the first early life nutrition product of its kind to receive such approval from Australian authorities.
This decision by Food Standards Australia New Zealand (FSANZ) was finalised in April 2025. The formal endorsement came after the Australia and New Zealand Food Ministers Meeting.
The approval permits the use of MFGM as a nutritive substance in infant formula products throughout Australia, effective immediately. However, it does not extend to New Zealand, which recently opted out of the joint infant formula products standard shared with Australia.
Lacprodan MFGM-10 is a bovine MFGM ingredient. According to the company, it has the most clinical documentation supporting its benefits for infant nutrition and immune health. It can be labelled as “Milk fat globule membrane-enriched whey protein concentrate” in Australia. MFGM naturally occurs in human milk and is composed of phospholipids, sphingolipids, and gangliosides.
Earlier this year, the European Union confirmed that Lacprodan MFGM-10 is not considered a novel food, allowing its incorporation in products for both infants and adults across the EU.
Arla Foods Ingredients Specialised Nutrition senior director Jakob Madsen Pedersen said: “Following the recent positive decision about Lacprodan MFGM-10 in the EU, this is another highly welcome regulatory development. We’re delighted that its many clinically supported benefits for infants are now also available in Australia.”
